Skip to content
Screener

Tango Therapeutics TNGX EPS (Basic)

EPS (Basic) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Amgen logo
AmgenAMGN
$4.40+65.4%
Gilead Sciences logo
Gilead SciencesGILD
-$8.45-638%
Exelixis logo
ExelixisEXEL
$0.85+25.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$1.11-35.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$0.60-445%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Numerator:
Net loss$(45,514)$(39,876)
Denominator:
Weighted-average common stock outstanding – basic and diluted143,576,292110,301,256
Net loss per common share – basic and diluted$(0.32)$(0.36)

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's EPS (basic)?
Tango Therapeutics (TNGX) reported EPS (basic) of -$0.32 in Q1 2026.
How has Tango Therapeutics's EPS (basic) changed year-over-year?
Tango Therapeutics's EPS (basic) increased by 11.1% year-over-year, from -$0.36 to -$0.32.
What is the long-term trend for Tango Therapeutics's EPS (basic)?
Over 4 years (2021 to 2025), Tango Therapeutics's EPS (basic) has grown at a -1.9% compound annual growth rate (CAGR), from -$0.94 to -$0.87.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Tango Therapeutics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude